eTable 1. Univariable and multivariable regression analyses were used to identify variables associated with hypogammaglobulinemia in patients who had been treatment for more than 3 years.

Variable	Hypogammaglobulinemia (n=38/135)			
	Univariable		Multivariable	
	OR	95% CI	OR	95% CI
Age at RTX initiation, y	0.991	0.96-1.023		
Sex				
Female	0.907	0.222-3.708		
Male	Ref.			
Duration before RTX treatment, y	1.015	0.933-1.104		
Duration of RTX treatment, y	1.355	1.166-1.574	1.246	1.011-1.536
Mean annual rituximab dose (g/year)	0.034	0.007-0.17	0.047	0.006-0.36
Mitoxantrone treatment				
Yes	5.734	2.379-13.823	3.275	1.077-9.956
No	Ref.		Ref.	
Comorbidity				
Yes	2.282	0.982-5.304		
No	Ref.			
EDSS score at RTX initiation	1.135	0.952-1.355		
IgG level at RTX initiation				
<6 g/L	3	0.576-15.638		
≥6 g/L	Ref.			

BMI				
>25 kg/m^2	2.953	1.263-6.907	5.712	1.656-19.708
≤25 kg/m^2	Ref.		Ref.	
FCG polymorphism (n=89)				
FF (n=50)	0.972	0.169-5.607		
VV or VF (n=39)	Ref.			

Abbreviations: RTX=rituximab; OR=odds ratio; 95% CI=95% confidence interval; y=year;

EDSS=Expanded Disability Status Scale; BMI=body mass index

eTable 2. Univariable and multivariable regression analyses were performed to identify variables associated with infections.

	Patients with infections (n=58)			
	Univariable		Multivariable	
	OR	95% CI	OR	95% CI
Age at RTX initiation, y	1.03	1.004-1.057		
Sex				
Female	1.291	0.157-10.613		
Male	Ref.			
Duration before RTX treatment, y	1.061	0.997-1.131		
Duration of RTX treatment, y	1.096	1.015-1.183		
Relapses during rituximab treatment, n	1.475	1.013-2.147	1.665	1.112-2.494
Mean annual rituximab dose (g/year)	0.874	0.533-1.434		
Mitoxantrone treatment				
Yes	2.036	0.905-4.582		
No	Ref.			
Comorbidity				
Yes	2.047	0.979-4.28		
No	Ref.			
IgG level at RTX initiation				
<6 g/L	1.514	0.327-7.018		

≥6 g/L	Ref.			
EDSS score at RTX initiation	1.448	1.229-1.706	1.451	1.227-1.715
BMI				
>25 kg/m^2	1.335	0.633-2.813		
≤25 kg/m^2	Ref.			
IgG level <4 g/L during rituximab treatment				
Yes	2.729	0.96-7.755		
No	Ref.			
IgM level <0.4 g/L during rituximab treatment				
Yes	1.216	0.644-2.296		
No	Ref.			
IgA level <0.7 g/L during rituximab treatment				
Yes	0.821	0.396-1.705		
No	Ref.			

Abbreviations: RTX=rituximab; OR=odds ratio; 95% CI=95% confidence interval; y=year; EDSS=Expanded Disability Status Scale; BMI=body mass index